logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Commentary

Measles and rubella vaccine microneedle patch: new hope to reach the unreached children

Coulborn RM, Danet C, Alsalhani A
2024-04-29 • Lancet
2024-04-29 • Lancet
Worldwide, more than 99% of the burden of measles infections and deaths affects populations in low-income and middle-income countries. Measles accounts for 3% of the global mortality of ...
Journal Article
|
Research

Evaluation of the stability of measles vaccine out of the cold chain under extended controlled temperature conditions

Juan-Giner A, Alsalhani A, Panunzi I, Lambert V, Van Herp M,  et al.
2020-02-08 • Vaccine
2020-02-08 • Vaccine
Measles outbreaks occur periodically in remote and difficult to reach areas in countries such as the Democratic Republic of Congo. The possibility to keep measles vaccines at temperature...
Journal Article
|
Letter

Developing countries can make the mRNA vaccines they need

Prabhala A, Alsalhani A
2022-01-31 • Nature Human Behaviour
2022-01-31 • Nature Human Behaviour
Journal Article
|
Pre-Print

MSF Access Campaign drug-resistant tuberculosis research and development case study May 2020

Cox V, Perrin C, Athersuch K, Martin M M, Alsalhani A
2020-06-01 • OSF Preprints
2020-06-01 • OSF Preprints
Two novel drugs, bedaquiline and delamanid, have recently become available to treat drug resistant tuberculosis (DR-TB) after many decades of little innovation in the field of DR-TB trea...
Journal Article
|
Commentary

Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study

Perrin C, Athersuch K, Elder G, Martin M, Alsalhani A
2022-04-19 • BMJ Global Health
2022-04-19 • BMJ Global Health
Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the nitroimidazole delamanid—as well as pretomanid from the same class of drugs as delamanid—have recently ...